UNSPSC 51145302: Pramiracetam

This classification denotes a neuroprotective agent with the molecular formula C14H27N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4449F8I3LE, chemically known as 2,1,3-benzothiadiazole, 5-chloro-4-(2-imidazolin-2-ylamino)- but more generally known as pramiracetam, which bears US NIH Compound Identifier 5487. European Medicines Agency schedules Pramiracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09991MIG. The term PRAMIRACETAM is an International Non-Proprietary Name.

UNSPSC 51145302 Pramiracetam, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The three opportunities posted since early 2026 involve naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs — none of which constitute pramiracetam procurement. The code's nominal scope (a nootropic pharmaceutical ingredient) does not match the actual purchasing activity tagged under it, suggesting either miscategorization in the procurement systems or a lack of meaningful demand for pramiracetam itself at the state and local level.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Minnesota Department of Administration's Office of State Procurement (administering MMCAP) posted an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across multiple states including Oregon, with proposals due March 26, 2026; and the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs. Geographic activity centers on Florida, Minnesota and MMCAP-participating states, and Texas, with no clear pattern of repeat buying under this specific code. The mismatch between the code's defined pharmaceutical and recent opportunities suggests this code does not represent active state and local procurement volume worth pursuing at present.